correct me if wrong,but I believe they said that they have introduced this possibility,in the past months. In my view success now depends on pharma QC development and launch. The clinical market is too slow to take up the technology . Anyway the current MC of 2? million makes this a compelling investment..i expect to exit with a profit at MC 18 million,Shares 0.015. The main risk is Astra zenica not proceeding.
Ann: Renounceable Rights Issue Results, page-7
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.98M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 62 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 1005518 | 2 |
View Market Depth
| Last trade - 10.04am 14/10/2024 (20 minute delay) ? |
| LBT (ASX) Chart |
Day chart unavailable